Targeting delavirdine/atevirdine resistant HIV-1: Identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 19, 1996, Pages 3769-3789

  Romero, Donna L ^a   Olmsted, Robert A ^a   Poel, Toni Jo ^a   Morge, Raymond A ^a   Biles, Carolyn ^a   Keiser, Barbara J ^a   Kopta, Laurice A ^a   Friis, Jan M ^a   Hosley, John D ^a   Stefanski, Kevin J ^a   Wishka, Donn G ^a   Evans, David B ^a   Morris, Joel ^a   Stehle, Randy G ^a   Sharma, Satish K ^a   Yagi, Yoshihiko ^a   Voorman, Richard L ^a   Adams, Wade J ^a   Tarpley, W Gary ^a   Thomas, Richard C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEVIRDINE; ATEVIRDINE MESYLATE; BHAP DERIVATIVE; DELAVIRDINE; PIPERAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RESISTANCE; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; VIRUS RECOMBINANT;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; DRUG STABILITY; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; INDOLES; MOLECULAR STRUCTURE; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9544229686     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960158n     Document Type: Article

References (54)

1. Scrip. US panel clears GW's Epivir and Roche's Invirase; Nov. 14, 1995; p 22.
2. Kellam, P.; Boucher, C. A. B.; Larder, B. A. Fifth mutation in a human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1934-1938.
3. Larder, B. A.; Darby, G.; Richman, D. D. Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT). Science 1989, 243, 1731-1734.
4. Larder, B. A.; Darby, G.; Richman, D. D. HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy. Science 1999, 243, 1731-1734.
5. St. Clair, M. H.; Martin, J. L.; Tudor-Williams, G.; Bach, M. C.; Vavro, C. L.; King, D. M.; Kellam, P.; Kemp, S. D.; Larder, B. A. Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase. Science 1991, 253, 1557-1559.
6. Romero, D. L. Atevirdine Mesylate. Drugs Future 1994, 19 (1), 9-12.
7. Romero, D. L. Delavirdine Mesylate. Drugs Future 1994, 19 (3), 238-242.
8. Nunberg, J. H.; Schleif, W. A.; Boots, E. J.; O'Brien, J. A.; Quintero, J. C.; Hoffman, J. M.; Emini, E. A.; Goldman, M. E. Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors. J. Virol. 1991, 65, 4887-4892.
9. Richman, D.; Shih, C.-K.; Lowry, I.; Rose, J.; Prodanovich, P.; Goff, S.; Griffin, J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11241-11245.
10. De Vreese, K.; Debyser, Z.; VanDamme, A.-M.; Pauwels, R.; Desmter, J.; DeClerq, E.; Anne, J. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology 1992, 188, 900-904.
11. Mellors, J. W.; Dutschman, G. E.; Im, G.-J.; Tramontano, E.; Winkler, S. R.; Cheng, Y.-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 1992, 41, 446-451.
12. (a) Freimuth, W. W. Delavirdine mesylate a potent non-nucleoside reverse transcriptase inhibitor of HIV-1: virology, pharmacokinetics, safety and clinical surrogate marker response. In Proceedings of the Fourth Triennial Symposium on New Directions in Antiviral Chemotherapy; Mills, J. Ed.; Plenum Press: New York, in press.
13. (b) Wathen, L. K.; Freimuth, W. W.; Batts, D. H.; Cox, S. R. Phenotypic and genotypic characterization of HIV-1 viral isolates from patients treated with combined AZT and delavirdine mesylate therapy. Third International HIV Drug Resistance Workshop, Kauai, Hawaii, Aug. 2-5, 1994; Abstract 42.
14. (c) Aristoff, P. A. BHAPs. DN&P 1995, 8 (3), 151-155.
15. Sardana, V. V.; Emini, E. A.; Gotlib, L.; Graham, D. J.; Lineberger, D. W.; Long, W. J.; Schlabach, A. J.; Wolfgang, J. A.; Condra, J. H. Functional Analysis of HIV-1 Reverse Transcriptase Amino Acids Involved in Resistance to Multiple Non-nucleoside Inhibitors. J. Biol. Chem. 1992, 267, 17526-17530.
16. Dueweke, T. J.; Pushkarskaya, T.; Poppe, S. M.; Swaney, S. M.; Zhao, J. Q.; Chen, I. S. Y.; Stevenson, M.; Tarpley, W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4713-4717.
17. U-90152S, U-90152E, and U-90152T are different crystal forms of the mesylate salt of U-90152 (delavirdine).
18. Mellors, J. W.; Larder, B. A.; Schinazi, R. F. Mutations in the HTV-1 Reverse Transcriptase and Protease Associated with Drug Resistance. Int. Antiviral News 1995, 3, 8-13.
19. De Clercq, E. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors. AIDS 1994, 8 (7), 1020-1021.
20. Adams, W. J.; Voorman, R. Unpublished results.
21. Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; Tan, C.-K.; Voorman, R. L.; Reusser, F.; Althaus, I. W.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G.; Aristoff, P. A. Discovery, Synthesis and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. J. Med. Chem. 1994, 37, 999-1014.
22. Romero, D. L.; Morge, R. A.; Genin, M. J.; Biles, C.; Busso, M.; Resnick, L.; Althaus, I. W.; Reusser, F.; Thomas, R. C.; Tarpley, W. G. Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships of Novel Substituted Indole Analogues and the Identification of 1-[(5-Methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine Monomethanesulfonate (U-90152S), a Second-Generation Clinical Candidate. J. Med. Chem. 1993, 36, 1505-1508.
23. Staton, B. A.; Johnson, M. G.; Friis, J. M.; Adams, W. J. Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J. Chromatogr. 1995, B668, 99-106.
24. Miwa, G. T.; Walsh, J. S.; Kedderis, G. L.; Hollenberg, P. F. The Use of Intramolecular Isotope Effects to Distinguish between Deprotonation and Hydrogen Atom Abstraction Mechanisms in Cytochrome P-450- and Peroxidase-catalyzed N-Demethylation Reactions. J. Biol. Chem. 1983, 258, 14445-14449.
25. Pettit, F. H.; Ziegler, D. M. The Catalytic Demethylation of N,N-dimethylaniline-N-oxide by Liver Microsomes. Biochem. Biophys. Res. Commun. 1963, 13, 193-197.
26. Karki, S. B.; Dinnocenzo, J. P.; Jones, J. P.; Korzekwa, K. R. Mechanism of Oxidative Amine Dealkylation of Substituted N,N-dimethylanilines by Cytochrome P-450: Application of Isotope Effect Profiles. J. Am. Chem. Soc. 1995, 117, 3657-3664.
27. Foye, W. O. Principles of Medicinal Chemistry; Lea & Febiger: Philadelphia, 1981; p 101.
28. Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Pate, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241.
29. Skoog, M. T.; Hargrave, K. D.; Miglietta, J. J.; Kopp, E. B.; Merluzzi, V. Inhibition of HIV-1 Reverse Transcriptase and Virus Replication by a Non-Nucleoside Dipyridodiazepinone BI-RG-587 (Nevirapine). Med. Res. Rev. 1992, 12, 27-40.
30. Anstadt, R. A.; Schwende, F. J.; Sedlock, M. L.; Voorman, R.; Wurzer, G. M. Preclinical Pharmacokinetic Evaluation of Several Bis(heteroaryl)piperazine (BHAP) analogs, non-nucleoside reverse transcriptase inhibitors (RTI). 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sept. 29-Oct. 2, 1991; Poster 1337.
31. T. J. Poel, R. C.; Thomas, D. L.; Romero, M. J.; Hosley, R. A.; Morge, C.; Biles, F.; Reusser, I. W.; Althaus, W. C.; Schinzer, D. J.; Platzer. Second Generation Bisheteroarylpiperazine (BHAP) HIV-1 Reverse Transcriptase Inhibitors. Enhancement of Antiviral Activity and Aqueous Solubility via 5- and 6-Substitution of the Indole Ring. 205th American Chemical Society National Meeting, Denver, CO, Mar. 28-Apr. 2, 1993.
32. Mayland Chang, et. al., Pharmacia & Upjohn, Inc., Drug Metabolism Research, unpublished results.
33. Compound 35 was poorly soluble in the standard 80% PG vehicle. Randall G. Stehle and Kevin J. Stefanski, Pharmacia & Upjohn, Inc., DDR&D Pharmaceutics, private communication.
34. Streitwieser, A.; Heathcock, C. H. Introduction to Organic Chemistry; Macmillan Publishing Co.: New York, 1981; pp 736-737.
35. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Deibel, M. R.; Chou, K.-C.; Kezdy, F. J.; Romero, D. L.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Steady-State Kinetic Studies with the Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor U-87201E. J. Biol. Chem. 1993, 268, 6119-6124.
36. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Deibel, M. R.; Chou, K.-C.; Kezdy, F. J.; Romero, D. L.; Palmer, J. R.; Thomas, R. C.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E. Biochemistry 1993, 32, 6548-6554.
37. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Deibel, M. R.; Chou, K.-C.; Kezdy, F. J.; Thomas, R. C.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Kinetic Studies with the Non-nucleoside Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitor U-90152E. Biochem. Pharmacol. 1994, 47, 2017-2028.
38. IIIB with Reduced Replication Phenotypes. J. Virol. 1996, 70, 3699-3705.
39. Kleim, J.-P.; Bender, R.; Billhardt, U.-M.; Meichsner, C.; Riess, G.; Rosner, M.; Winkler, I.; Paessens, A. Activity of a Novel Quinoxaline Derivative against Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Viral Replication. Antimicrob. Agents Chemother. 1993, 37, 1659-1664.
40. Conway, B. G.; Jeganathan, A.; Gage, J. R. Chemical Research Preparations, Pharmacia & Upjohn, Inc., private communication.
41. Kroon, C.; Maassen van den Brink, A.; Vlietstra, E. J.; Salemink, C. A. Deazapurine derivatives XV. Syntheses of some mono- and difluoroimidazo[4,5-b]- and [4,5-c]pyridines. Recl. Trav. Chim. Pay-Bas 1976, 95, 127-156.
42. Clark, J. H.; Macquarrie, D. J. The Synthesis of Organofluorine Compounds using Potassium Fluoride-tetraphenylphosphonium Bromide Systems. Tetrahedron Lett. 1987, 28, 111-114.
43. When chlorine was present in the pyridine ring, a dealkylative deprotection employing 1-chloroethyl chloroformate was used to debenzylate; see: Olofson, R. A.; Martz, J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T. J. Org. Chem. 1984, 49, 2081. DeShong, P.; Kell, D. A. Tetrahedron Lett. 1986, 27, 3979.
44. When chlorine was present in the pyridine ring, a dealkylative deprotection employing 1-chloroethyl chloroformate was used to debenzylate; see: Olofson, R. A.; Martz, J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T. J. Org. Chem. 1984, 49, 2081. DeShong, P.; Kell, D. A. Tetrahedron Lett. 1986, 27, 3979.
45. Genin, M. J.; Biles, C.; Romero, D. L. A Novel Method for the t-Butylation of Aromatic Amines. Tetrahedron Lett. 1993, 4301-4304.
46. Morris, J.; Wishka, D. G. An Efficient Synthesis of Aromatic Acetonyl Imines. J. Org. Chem. 1995, 60, 2642-2644.
47. Hennion, G. F.; Hanzel, R. S. The Alkylation of Amines with t-Acetylenic Chlorides. Preparation of Sterically Hindered Amines. J. Am. Chem. Soc. 1960, 82, 4908.
48. Kopka, I. E.; Fataftah, Z. A.; Rathke, M. W. Preparation of a Series of Highly Hindered Secondary Amines, Including Bis-(trimethylcarbinyl)amine. J. Org. Chem. 1980, 45, 4616-4622.
49. Kang, J.; Kim, K. S. N-Cyclopropylation of Aromatic Amines. J. Chem. Soc. Chem. Comm. 1987, 897-898. For a newer method published subsequent to our work, see: Gillaspy, M. L.; Lefker, B. A.; Hada, W. A.; Hoover, D. J. A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine. Tet. Lett. 1995, 36, 7399-7402.
50. Kang, J.; Kim, K. S. N-Cyclopropylation of Aromatic Amines. J. Chem. Soc. Chem. Comm. 1987, 897-898. For a newer method published subsequent to our work, see: Gillaspy, M. L.; Lefker, B. A.; Hada, W. A.; Hoover, D. J. A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine. Tet. Lett. 1995, 36, 7399-7402.
51. Kuraiski, T.; Castle, R. N. J. Het. Chem. 1964, 1, 42.
52. Sharma, S. K.; Evans, D. B.; Vosters, A. F.; McQuade, T. J.; Tarpley, W. G. Metal Affinity Chromatography of Recombinant HIV-1 Reverse Transcriptase Containing a Human Renin Cleavable Metal Binding Domain. Biotechnol. Appl. Biochem. 1991, 14, 69-81.
53. Chattopadhyay, D.; Evans, D. B.; Deibel, M. R., Jr.; Vosters, A. F.; Eckenrode, F. M.; Einspahr, H. M.; Hui, J. O.; Tomasselli, A. G.; Zurcher-Neely, H. A.; Heinrikson, R. L.; Sharma, S. K. Purification and Characterization of Heterodimeric Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Produced by in vitro Processing of p66 with Recombinant HIV-1 Protease. J. Biol. Chem. 1992, 267, 14227-14232.
54. 50 values obtained in the enzyme assays.